Her2阳性乳癌组织TopⅡα的表达及临床意义

目的探讨人表皮因子受体基因2（Her2）阳性乳房浸润性导管癌DNA拓扑异构酶Ⅱα（TopⅡα）蛋白表达和基因变异的相关性,以及两者与乳癌临床病理特征关系。方法选取我院乳腺病诊疗中心组织标本库中2013年1—6月Her2阳性乳房浸润性导管癌标本76例。应用荧光原位杂交（FISH）、免疫组织化学（IHC）技术分别对76例乳癌组织的TopⅡα基因、蛋白进行检测和分析。结果 TopⅡα基因变异与TopⅡα蛋白表达无显著相关性（P〉0.05）;TopⅡα蛋白表达和基因变异与病人年龄、绝经情况、组织学分级及AJCC分期均无显著相关性（P〉0.05）,而与有无腋窝淋巴结转移显著相关（χ2=8.546、7.285,P〈0.05）。结论 TopⅡα蛋白表达与基因变异无相关性,且二者均只与乳房浸润性导管癌腋窝淋巴结转移显著相关,临床上TopⅡα蛋白的检测更适用于对蒽环类化疗药物的疗效评价。

TOPⅡα IN HER2 POSITIVE BREAST CANCER： ITS EXPRESSION AND CLINICAL SIGNIFICANCE

Objective To investigate the correlation of Top Ⅱα protein expression with Top Ⅱα gene aberration in Her2 positive breast invasive ductal carcinoma （BIDC）. Methods Specimens of 76 patients with Her2-positive BIDC treated in our hospital （from January 2013 to June 2013） were collected from tissue bank of this hospital. The Top Ⅱα gene aberrations and Top Ⅱα protein expression were detected and analyzed by using fluorescence in situ hybridization and immunohistochemistry, respec tively. Results No significant correlation was found between Top Ⅱα gene aberration and Top Ⅱα protein expression （P〉 0.05）. The expression of Top Ⅱα protein and TopⅡα gene aberration were not associated with patient age, menopause condition, histological grade and clinical stage of the cancer （P〉0.05）, but obviously related to with or without axillary lymph node metasta- ses （x2=8.546,7.285 ;P〈0.05）. Conclusion Top Ⅱα protein expression is not correlated with Top Ⅱα gene aberration, which are notably associated with axillary lymph node metastases. Clinically, the detection of Top Ⅱα protein is more suitable for the evaluation of clinical efficacy of anthracyeline based regimen.